MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Personalis, Inc. - Common Stock (NQ:PSNL)

5.980 -0.010 (-0.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Personalis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse
From Personalis, Inc.
Via Business Wire
News headline image
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference
From Personalis, Inc.
Via Business Wire
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Personalis Through 7 Analysts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
Personalis Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) ↗
 
Via Benzinga
News headline image
Analyst Expectations For Personalis's Future ↗
 
Via Benzinga
News headline image
Personalis Reports First Quarter 2025 Financial Results
From Personalis, Inc.
Via Business Wire
News headline image
Personalis’ NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Announce First Quarter 2025 Financial Results
From Personalis, Inc.
Via Business Wire
News headline image
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection
From Personalis, Inc.
Via Business Wire
News headline image
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It. ↗
A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences. 
Via Investor's Business Daily
News headline image
What 5 Analyst Ratings Have To Say About Personalis ↗
 
Via Benzinga
News headline image
Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference
From Personalis, Inc.
Via Business Wire
News headline image
This Blueprint Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Cathie Wood-Led Ark Invest Roblox, Roku, UiPath As Markets Take A Dip ↗
Ark Invest made significant trades on Friday, selling shares of RBLX, ROKU, PATH and buying shares of IBTA, PSNL, ABSI, and RXRX. 
Via Benzinga
News headline image
New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Reports Fourth Quarter and Full Year 2024 Financial Results
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference
From Personalis, Inc.
Via Business Wire
News headline image
Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Personalis, Inc.
Via Business Wire
News headline image
New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue
From Personalis, Inc.
Via Business Wire
News headline image
Dow Surges Over 600 Points, Gold Jumps 1.5% ↗
 
Via Benzinga
Topics Stocks
News headline image
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NASDAQ:PSNL),(NASDAQ:TEM),(NASDAQ:CKPT) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher ↗
 
Via Benzinga
News headline image
Mission Produce, Nvidia, Humacyte, BlackBerry And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Stock Of The Day: Where Does The Merck Downtrend End? ↗
Shares of Merck & Co (MRK) continue to trend lower. If they reach the $95.00 level, there is a good chance they find support and reverse. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story